60 research outputs found
Evaluation of community pharmacists’ readiness to implement the Falsified Medicines Directive (Directive 2011/62/EC): an English cross-sectional survey with geospatial analysis
Asthma and COPD medicines prescription-claims:A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (Jan 2019 to Oct 2020)
Quality evaluation of community pharmacy Blood Pressure (BP) screening services:an English cross-sectional survey with geospatial analysis
An evaluation of the knowledge and perceptions of pharmacy staff and pre-registration students of e-cigarettes use:A systematic review
INTRODUCTION: Pharmacy staff are a trusted source of advice on the safe and appropriate use of medicines and devices. Retail pharmacies deliver smoking cessation services and sell e-cigarettes in the UK. This review asks ‘what knowledge, experience and ability do staff have to support e-cigarette users to quit smoking’. METHODS: A systematic literature search was undertaken drawn on predefined eligibility criteria and a comprehensive search strategy following the PRISMA guideline. Eligible papers reported survey-research published in English from 2015 to 2020. PubMed, Google Scholar, OVID, EMBASE and MEDLINE Databases were searched. No restrictions on study design or language were applied. Two reviewers independently screened for inclusion/exclusion and then extracted the relevant information from the articles for synthesis. RESULTS: Of 12 potentially eligible full-text studies, 1 was a duplicate, 7 were excluded as per eligibility criteria. Four papers were finally included in this literature review. Two studies indicated that pharmacy staff are less confident in giving advice on e-cigarette use. Knowledge on the adverse effects of e-cigarettes compared to traditional smoking cessation aids remain unclear. In one study, 42% of community pharmacists did not believe that e-cigarettes could be used for smoking cessation. Three studies identified need for specific regulations and professional support. The overall certainty of the evidence is ‘low’ or ‘very low’, with moderate levels of bias. CONCLUSION: Pharmacists may be well placed to implement e-cigarette smoking cessation interventions, but most practitioners lacked knowledge and ability to support these customers citing unclear risk of harm. Pharmacists felt secure in recommending traditional cessation tools. Further regulation, guidelines and training is needed. Findings may be less generalizable in countries where e-cigarettes are banned. Their extent of knowledge, experience and ability to support users of e-cigarettes within their community to quit smoking is lacking
Gonadorelins adherence in prostate cancer:A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020)
Development and initial validation of a postal survey evaluation of community pharmacists' opinion regarding falsified (counterfeit) medicines in Hampshire (UK)
Context: Falsified-medicines pose a worldwide problem to patients, healthcare professionals, pharmaceutical companies, and governments. Community pharmacists are usually the last points of contact with patients and can protect them by quarantining falsified medicines. Hence, their opinions are valuable in exploring how the profession can combat this.
Aims: To explore the opinion of pharmacists with respect to falsified medicines.
Methods: A postal survey was developed and distributed to 359 pharmacies via the local pharmaceutical committee in Hampshire, UK. Descriptive statistics and hypothesis testing was conducted. Hypothesis testing (95% CI, α = 0.05) will be conducted to identify any gender differences, differences based on years of experience and differences based on number of working hours per week.
Results: A 14% response rate was achieved. Pharmacists surveyed believe that falsified-medicines pose a significant problem to the profession on a five-point Likert scale (4.02 ± 1.078). A pharmacist’s intervention can prevent or disrupt the supply to patients (4.12 ± 0.824) and training courses can improve pharmacist’s knowledge (4.06 ± 0.843). Pharmacists are not confident and capable in identifying falsified-medicines (2.62 ± 1.105). This is surprising and unexpected because pharmacists are medicines-expert. A 10-item scale is validated (72.2% Cronbach alpha).
Conclusions: Falsified-medicines pose a small but significant and growing challenge to the profession. There is underutilization of the high street community pharmacist in identifying falsified-medicines. Healthcare professionals should report suspect counterfeits to the MHRA
Acute oxygen therapy:a cross-sectional study of prescribing practices at an English Hospital immediately before COVID-19 pandemic
An evaluation of community pharmacist perception of the misuse and abuse of over-the-counter co-codamol in Cornwall and Devon, UK:a cross-sectional survey
Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders:a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset
OBJECTIVE: To investigate monthly prescription refills for common immunosuppressive/immunomodulatory therapy (sulfasalazine, hydroxychloroquine, azathioprine, methotrexate, leflunomide) prescriptions in England during the complete first wave of the COVID-19 pandemic. Secondary analysis examined unit cost analysis and regional use. DESIGN AND SETTING: A national cohort of community-based, primary care patients who anonymously contribute data to the English Prescribing Dataset, dispensed in the community in England, were included. Descriptive statistics and interrupted time series analysis over 25 months (14 months before, 11 months after first lockdown) were evaluated (January 2019 to January 2021, with March 2020 as the cut-off point). OUTCOME MEASURES: Prescription reimbursement variance in period before the pandemic as compared with after the first lockdown. RESULTS: Fluctuation in monthly medicines use is noted in March 2020: a jump is observed for hydroxychloroquine (Mann-Whitney, SE 14.652, standardised test statistic 1.911, p value=0.059) over the study period. After the first lockdown, medicines use fluctuated, with wide confidence intervals. Unit-cost prices changed substantially: sulfasalazine 33% increase, hydroxychloroquine 98% increase, azathioprine 41% increase, methotrexate 41% increase, leflunomide 20% decrease. London showed the least quantity variance, suggesting more homogeneous prescribing and patient access compared with Midlands and East of England, suggesting that some patients may have received medication over/under requirement, representing potential resource misallocation and a proxy for adherence rates. Changepoint detection revealed four out of the five medicines’ use patterns changed with a strong signal only for sulfasalazine in March/April 2020. CONCLUSIONS: Findings potentially present lower rates of adherence because of the pandemic, suggesting barriers to care access. Unit price increases are likely to have severe budget impacts in the UK and potentially globally. Timely prescription refills for patients taking immunosuppressive/immunomodulatory therapies are recommended. Healthcare professionals should identify patients on these medicines and assess their prescription-day coverage, with planned actions to flag and follow-up adherence concerns in patients
- …